How MUSC and Revival Plan to Unclog the Device Pipeline

MUSC and Revival Healthcare Capital launch a five-year deal to fast-track US medical device innovation

26 May 2026

MUSC and Revival Healthcare Capital signed a five-year strategic partnership on 29 April 2026 to accelerate the evaluation and commercial development of medical devices, formalising a structure designed to move from clinical insight to market faster than existing industry timelines allow.

Under the agreement, MUSC surgeons and clinical experts will advise Revival's portfolio companies, providing procedural validation before capital is committed to any device. Revival, in turn, gains early access to device opportunities originating within MUSC, one of the country's leading academic medical centres. Neither party has disclosed which device categories are prioritised.

The deal targets a well-documented problem. Device development in the United States is expensive and slow, relying on clinical validation that most investment firms cannot secure independently. MUSC president David Cole described the partnership's goal as strengthening the path from clinical insight to real-world impact.

Revival senior partner Todd Pope called it "a repeatable, high-velocity model," language that signals ambitions beyond a single bilateral arrangement. If the structure performs as intended, other academic health systems facing stalled innovation pipelines may adopt a similar approach.

For the broader medtech sector, compressing a development cycle that typically spans years carries consequences well beyond South Carolina.